Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Friday morning. The brokerage issued a hold rating on the medical research company’s stock.

CTSO has been the subject of several other research reports. D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a report on Monday, January 13th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Down 0.8 %

CTSO opened at $1.30 on Friday. The firm has a 50-day simple moving average of $0.98 and a two-hundred day simple moving average of $1.04. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The company has a market capitalization of $71.08 million, a PE ratio of -3.61 and a beta of 0.61. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Institutional Trading of Cytosorbents

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp raised its position in Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after purchasing an additional 16,701 shares during the period. Avenir Corp raised its position in Cytosorbents by 4.0% in the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock worth $2,815,000 after purchasing an additional 118,387 shares during the period. Raymond James Financial Inc. purchased a new stake in Cytosorbents in the 4th quarter worth about $99,000. Renaissance Technologies LLC raised its position in Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after purchasing an additional 8,400 shares during the period. Finally, Skylands Capital LLC raised its position in Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after purchasing an additional 26,195 shares during the period. 32.87% of the stock is owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.